According to FutureWise analysis the market for antiviral drugs in 2023 was US$ 61.42 billion, and is expected to reach US$ 84.84 billion by 2031 at a CAGR of 4.12%.

Antiviral drugs represent a specialized category of medications designed to combat viral infections. Unlike bacteria and other microorganisms, viruses cannot reproduce or perform metabolic processes independently; they rely on host cells for replication and dissemination. Antiviral drugs work by targeting key phases of the viral replication cycle. This can involve inhibiting the entry of viruses into host cells, disrupting the replication of viral genomes, or blocking the assembly and release of new viral particles, known as virions.

One prominent category of antiviral drugs is nucleoside/nucleotide analogs. These compounds imitate the structure of natural nucleotides and interfere with the synthesis of viral DNA or RNA, thereby impeding viral replication. Notable examples of nucleoside analogs include acyclovir, commonly used for herpes infections, and tenofovir, frequently prescribed for HIV.

Another class of antiviral agents is protease inhibitors, which target viral enzymes that are crucial for the replication of specific viruses, such as the human immunodeficiency virus (HIV) and hepatitis C virus (HCV). Common protease inhibitors include ritonavir and lopinavir/ritonavir, as well as glecaprevir/pibrentasvir.

Integrase inhibitors also play a vital role in antiviral therapy by targeting the enzyme integrase, which is essential for the integration of viral DNA into host cells. Examples in this category are raltegravir and dolutegravir.

Moreover, the field has seen the emergence of direct-acting antivirals, which focus on specific viral proteins or enzymes. For instance, polymerase inhibitors target HCV, while neuraminidase inhibitors are effective against the influenza virus. These targeted approaches enhance the effectiveness of antiviral therapy and improve patient outcomes.

FutureWise Market Research has published a report that provides an insightful analysis of Antiviral Drugs Market trends that are affecting the overall market growth.

Request a Free Sample @ https://www.futurewiseresearch.com/contact.aspx?rpt=7886&type=requestsample

Antiviral Drugs Market Segmentation:

By Type

  • Branded
  • Generic

By Drug Class

  • DNA Polymerase Inhibitors
  • Reverse Transcriptase Inhibitors
  • Protease Inhibitors
  • Neuraminidase Inhibitors
  • Others

By Application

  • HIV
  • Hepatitis
  • Herpes
  • Influenza
  • Others 

By Region

  • North America
  • Europe
  • Asia-Pacific
  • Latin America
  • Middle East and Africa

Competitive Landscape in Antiviral Drugs Market:

  • Gilead Sciences
  • F. Hoffmann-La Roche AG
  • GlaxoSmithKline plc
  • AbbVie
  • Merck & Co. Inc.
  • Johnson And Johnson Services Inc.
  • Bristol-Myers Squibb Company
  • Cipla Inc.
  • Aurobindo Pharma
  • Dr Reddy’s Laboratories Ltd.
  • Glenmark Pharmaceuticals Ltd.

Buy now the latest version of this report: https://www.futurewiseresearch.com/checkout.aspx?ReportId=7886&license=multi

**Objectives of this Study: **

  1. To provide a comprehensive analysis of the Antiviral Drugs Market By Product Type, By Application and By Region.
  2. To offer detailed insights into factors such as drivers, restraints, trends, and opportunities, as well as segmental and regional influences on market growth.
  3. To evaluate current market trends and forecast micro-markets, presenting overall market projections in the form of data sets and PowerPoint presentations.
  4. To predict the market size in key regions, including North America, Europe, Asia Pacific, Latin America, and the Middle East and Africa.

                                                                                                                
Flexible Delivery Model:

  • We have a flexible delivery model and you can suggest changes in the scope/table of contents as per your requirement
  • The customization services offered are free of charge with the purchase of any license of the report.
  • You can directly share your requirements/changes to the current table of contents to: sales@futurewiseresearch.com